Protocol #GS-US-321-0102: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangiti

Project: Research project

Project Details

StatusFinished
Effective start/end date3/14/138/31/19

Funding

  • PPD Development (GS-US-321-0102)
  • Gilead Sciences, Inc. (GS-US-321-0102)